Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Ann Allergy Asthma Immunol ; 130(6): 713-717, 2023 06.
Article in English | MEDLINE | ID: covidwho-2273391

ABSTRACT

Despite their widespread clinical use, oral corticosteroids (OCSs) are well known to be associated with a myriad of adverse effects, including immunosuppression. By inhibiting transcription factors and affecting leukocyte function, prolonged OCS use leads to significant CD4 lymphopenia and often a decrease in serum immunoglobulin (Ig)G. Conversely, OCS use has minimal impact on circulating B cell, serum IgM, or serum IgA levels. Although there is a paucity of literature, individuals treated with prolonged OCS seem to typically maintain humoral response to various vaccinations despite hypogammaglobinemia, but this area warrants additional research, especially in the setting of the coronavirus disease 2019 pandemic. Individuals treated with prolonged OCS use are most at risk for opportunistic infections, especially those with underlying malignancy and history of bone marrow transplant. Risk mitigation strategies to decrease infectious complication with OCS use include limiting the dose and duration of therapy, appropriately completing a full vaccination series, consideration for passive immunization, and prophylaxis against opportunistic infections.


Subject(s)
COVID-19 , Opportunistic Infections , Humans , Steroids , Adrenal Cortex Hormones/therapeutic use , Bone Marrow Transplantation , Opportunistic Infections/prevention & control , Opportunistic Infections/drug therapy
2.
RMD Open ; 8(2)2022 11.
Article in English | MEDLINE | ID: covidwho-2098013

ABSTRACT

OBJECTIVE: To conduct a systematic literature review (SLR) on the screening and prophylaxis of opportunistic and chronic infections in autoimmune inflammatory rheumatic diseases (AIIRD). METHODS: SLR (inception-12/2021) based on the following search domains: (1) infectious agents, (2) AIIRD, (3) immunosuppressives/immunomodulators used in rheumatology, (4) screening terms and (5) prophylaxis terms. Articles were retrieved having the terms from (1) AND (2) AND (3) plus terms from (4) OR(5). Databases searched: PubMed, Embase and Cochrane Library. EXCLUSION CRITERIA: studies on postoperative infections, paediatric AIIRD, COVID-19, vaccinations and non-Εnglish literature. Study quality was assessed with Newcastle-Ottawa scale for non-randomised controlled trials (RCTs), RoB-Cochrane for RCTs, AMSTAR2 for SLRs. RESULTS: From 5641 studies were retrieved, 568 full-text articles were assessed for eligibility, with 194 articles finally included. For tuberculosis, tuberculin skin test (TST) is affected by treatment with glucocorticoids and conventional synthetic disease modifying anti-rheumatic drugs (DMARDs) and its performance is inferior to interferon gamma release assay (IGRA). Agreement between TST and IGRA is moderate to low. For hepatitis B virus (HBV): risk of reactivation is increased in patients positive for hepatitis B surface antigen. Anti-HBcore positive patients are at low risk for reactivation but should be monitored periodically with liver function tests and/or HBV-viral load. Risk for Hepatitis C reactivation is existing but low in patients treated with biological DMARDs. For Pneumocystis jirovecii, prophylaxis treatment should be considered in patients treated with prednisolone ≥15-30 mg/day for >2-4 weeks. CONCLUSIONS: Different screening and prophylaxis approaches are described in the literature, partly determined by individual patient and disease characteristics.


Subject(s)
Antirheumatic Agents , COVID-19 , Opportunistic Infections , Rheumatic Diseases , Adult , Humans , Child , COVID-19/diagnosis , COVID-19/prevention & control , Antirheumatic Agents/adverse effects , Hepatitis B virus , Opportunistic Infections/diagnosis , Opportunistic Infections/etiology , Opportunistic Infections/prevention & control , Rheumatic Diseases/complications , Rheumatic Diseases/drug therapy
3.
World J Gastroenterol ; 27(27): 4276-4297, 2021 Jul 21.
Article in English | MEDLINE | ID: covidwho-1344407

ABSTRACT

Over the past decades, the treatment of inflammatory bowel diseases (IBD) has become more targeted, anticipating the use of immune-modifying therapies at an earlier stage. This top-down approach has been correlated with favorable short and long-term outcomes, but it has also brought with it concerns regarding potential infectious complications. This large IBD population treated with immune-modifying therapies, especially if combined, has an increased risk of severe infections, including opportunistic infections that are sustained by viral, bacterial, parasitic, and fungal agents. Viral infections have emerged as a focal safety concern in patients with IBD, representing a challenge for the clinician: they are often difficult to diagnose and are associated with significant morbidity and mortality. The first step is to improve effective preventive strategies, such as applying vaccination protocols, adopt adequate prophylaxis and educate patients about potential risk factors. Since viral infections in immunosuppressed patients may present atypical signs and symptoms, the challenges for the gastroenterologist are to suspect, recognize and diagnose such complications. Appropriate treatment of common viral infections allows us to minimize their impact on disease outcomes and patients' lives. This practical review supports this standard of care to improve knowledge in this subject area.


Subject(s)
Colitis , Inflammatory Bowel Diseases , Opportunistic Infections , Virus Diseases , Humans , Immunocompromised Host , Inflammatory Bowel Diseases/epidemiology , Inflammatory Bowel Diseases/therapy , Opportunistic Infections/diagnosis , Opportunistic Infections/epidemiology , Opportunistic Infections/prevention & control , Virus Diseases/epidemiology
4.
Gastroenterology ; 161(2): 681-700, 2021 08.
Article in English | MEDLINE | ID: covidwho-1330154

ABSTRACT

BACKGROUND AND AIMS: The effectiveness and safety of vaccinations can be altered by immunosuppressive therapies, and perhaps by inflammatory bowel disease (IBD) itself. These recommendations developed by the Canadian Association of Gastroenterology and endorsed by the American Gastroenterological Association, aim to provide guidance on immunizations in adult and pediatric patients with IBD. This publication focused on inactivated vaccines. METHODS: Systematic reviews evaluating the efficacy, effectiveness, and safety of vaccines in patients with IBD, other immune-mediated inflammatory diseases, and the general population were performed. Critical outcomes included mortality, vaccine-preventable diseases, and serious adverse events. Immunogenicity was considered a surrogate outcome for vaccine efficacy. Certainty of evidence and strength of recommendations were rated according to the GRADE (Grading of Recommendation Assessment, Development, and Evaluation) approach. Key questions were developed through an iterative online platform, and voted on by a multidisciplinary group. Recommendations were formulated using the Evidence-to-Decision framework. Strong recommendation means that most patients should receive the recommended course of action, whereas a conditional recommendation means that different choices will be appropriate for different patients. RESULTS: Consensus was reached on 15 of 20 questions. Recommendations address the following vaccines: Haemophilus influenzae type b, recombinant zoster, hepatitis B, influenza, pneumococcus, meningococcus, tetanus-diphtheria-pertussis, and human papillomavirus. Most of the recommendations for patients with IBD are congruent with the current Centers for Disease Control and Prevention and Canada's National Advisory Committee on Immunization recommendations for the general population, with the following exceptions. In patients with IBD, the panel suggested Haemophilus influenzae type b vaccine for patients older than 5 years of age, recombinant zoster vaccine for adults younger than 50 year of age, and hepatitis B vaccine for adults without a risk factor. Consensus was not reached, and recommendations were not made for 5 statements, due largely to lack of evidence, including double-dose hepatitis B vaccine, timing of influenza immunization in patients on biologics, pneumococcal and meningococcal vaccines in adult patients without risk factors, and human papillomavirus vaccine in patients aged 27-45 years. CONCLUSIONS: Patients with IBD may be at increased risk of some vaccine-preventable diseases. Therefore, maintaining appropriate vaccination status in these patients is critical to optimize patient outcomes. In general, IBD is not a contraindication to the use of inactivated vaccines, but immunosuppressive therapy may reduce vaccine responses.


Subject(s)
Gastroenterology/standards , Immunization/standards , Immunosuppressive Agents/adverse effects , Inflammatory Bowel Diseases/drug therapy , Opportunistic Infections/prevention & control , Vaccines, Inactivated/administration & dosage , Canada , Consensus , Evidence-Based Medicine/standards , Humans , Immunization/adverse effects , Immunocompromised Host , Inflammatory Bowel Diseases/diagnosis , Inflammatory Bowel Diseases/immunology , Inflammatory Bowel Diseases/mortality , Opportunistic Infections/diagnosis , Opportunistic Infections/immunology , Opportunistic Infections/mortality , Patient Safety , Risk Assessment , Risk Factors , Treatment Outcome , Vaccine Efficacy , Vaccines, Inactivated/adverse effects
7.
Transpl Infect Dis ; 22(5): e13327, 2020 Oct.
Article in English | MEDLINE | ID: covidwho-260203

ABSTRACT

Coronavirus disease 2019 (COVID-19) pandemic poses an increasing challenge for transplant community. Aggressive management measures are conductive to improve compliance and to lower the risk of intra-hospital infection. In this Personal Viewpoint essay, we shared experiences about management strategies of transplant patients outside hospital amid the epidemic. With the aid of Cloud Clinic service and telemedicine care, transplant patients could be regularly followed up and get medical consultation online. Furthermore, personal health education and mental health assistance are enrolled in our practice.


Subject(s)
Aftercare/organization & administration , COVID-19/prevention & control , Outpatient Clinics, Hospital/organization & administration , Telemedicine/organization & administration , Transplant Recipients , Aftercare/methods , Aftercare/standards , COVID-19/epidemiology , COVID-19/transmission , COVID-19/virology , China , Cloud Computing , Communicable Disease Control/organization & administration , Communicable Disease Control/standards , Humans , Immunocompromised Host , Opportunistic Infections/immunology , Opportunistic Infections/prevention & control , Outpatient Clinics, Hospital/standards , Pandemics/prevention & control , Patient Compliance , SARS-CoV-2/pathogenicity , Specialties, Surgical/organization & administration , Telemedicine/methods , Telemedicine/standards , Transplantation/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL